Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Zevia Q2 Sales $45.50M Beat $42.17M Estimate

Zevia (NYSE:ZVIA) reported quarterly sales of $45.50 million which beat the analyst consensus estimate of $42.17 million by 7.90 percent. This is a 32.45 percent increase over sales of $34.35 million the same period
byBenzinga Newsdesk
August 11, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Zevia (NYSE:ZVIA) reported quarterly sales of $45.50 million which beat the analyst consensus estimate of $42.17 million by 7.90 percent. This is a 32.45 percent increase over sales of $34.35 million the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Ocular Therapeutix Announced Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD; Said 80% of Subjects were Rescue-Free up to 6 months and 73% of Subjects Were Rescue-Free up to 7 months Following a Single OTX-…

By Charles Gross
September 27, 6:02 AM
Ocular Therapeutix, Inc. (NASDAQ: OCUL) today announced interim 7-month data from its U.S. Phase 1 clinical trial evaluating OTX-TKI, the Company's axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases.

OCUL